181 related articles for article (PubMed ID: 29198034)
1. Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study.
Schwegler C; Kaufmann D; Pfeiffer D; Aebi S; Diebold J; Gautschi O
Virchows Arch; 2018 Apr; 472(4):581-588. PubMed ID: 29198034
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
3. [Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma].
Fournier C; Greillier L; Fina F; Secq V; Nanni-Metellus I; Loundou A; Garcia S; Ouafik L; Tomasini P; Barlesi F
Rev Mal Respir; 2016 Nov; 33(9):751-756. PubMed ID: 27017063
[TBL] [Abstract][Full Text] [Related]
4. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
5. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
6. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
7. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
[TBL] [Abstract][Full Text] [Related]
11. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.
Ess SM; Herrmann C; Frick H; Krapf M; Cerny T; Jochum W; Früh M
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28557060
[TBL] [Abstract][Full Text] [Related]
13. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang Y; Wakelee HA; Neal JW
Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
[TBL] [Abstract][Full Text] [Related]
14. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
15. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
[TBL] [Abstract][Full Text] [Related]
16. [Association between the ALK Gene Status and the Efficacy of First-line
Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].
Chen M; Cao H; Ji Y; Mao Y; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):732-736. PubMed ID: 29167001
[TBL] [Abstract][Full Text] [Related]
17. Emerging targeted therapies in non-small cell lung cancer.
Khanal N; Ganti AK
Expert Rev Anticancer Ther; 2016; 16(2):177-87. PubMed ID: 26618563
[TBL] [Abstract][Full Text] [Related]
18. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
19. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
